Board Change • Jul 01
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. No experienced directors. 5 highly experienced directors. Independent Director G. van Heek is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Jun 04
Minerva Neurosciences, Inc. Announces Formation of Scientific Advisory Board Minerva Neurosciences, Inc. announced the formation of its Scientific Advisory Board (SAB), fulfilling a commitment made in connection with the Company’s PIPE financing announced on October 21, 2025. The SAB brings together distinguished researchers and clinicians with proven track records of advancing meaningful treatments in psychiatry and neuroscience. The SAB will advise on the Company’s research and development activities, including the ongoing Phase 3 confirmatory clinical trial (NCT07565428; MIN-101C19) of roluperidone for the treatment of negative symptoms of schizophrenia, as well as Minerva’s broader pipeline for patients with serious psychiatric conditions. Scientific Advisory Board Members include: Michael Davidson, M.D., Chief Medical Officer, Minerva Neurosciences; Philip Harvey, Ph.D., Professor of Psychiatry and Behavioral Sciences, University of Miami; Oliver Howes, M.D., Ph.D., Professor of Molecular Psychiatry, King's College London; Inder Kaul, M.D., Chief Medical Officer, Draig Therapeutics, Member, Minerva Neurosciences Board of Directors; Brian Kirkpatrick, M.D., Professor of Psychiatry, University of Arkansas for Medical Sciences; Remy Luthringer, Ph.D., Chief Executive Officer, Minerva Neurosciences; Avi Reichenberg, Ph.D., Professor of Psychiatry and Preventive Medicine, Icahn School of Medicine at Mount Sinai; Greg Strauss, Ph.D., Franklin Professor of Psychology and Neuroscience, University of Georgia. Announcement • May 28
Minerva Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Minerva Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering 
